{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:30:22Z","timestamp":1795026622586,"version":"4.10.2"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"2","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K08CA241400-01"],"award-info":[{"award-number":["K08CA241400-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA138738-05"],"award-info":[{"award-number":["R01 CA138738-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"MSKCC","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"MSKCC","doi-asserted-by":"publisher","award":["U54 OD020355-01"],"award-info":[{"award-number":["U54 OD020355-01"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation antigen (TNFRSF17; BCMA) induces high overall response rates; however, relapse occurs commonly. A reservoir of multiple myeloma cells lacking sufficient BCMA surface expression (antigen escape) may be implicated in relapse. We demonstrate that simultaneous targeting of an additional antigen\u2014here, G protein-coupled receptor class-C group-5 member-D (GPRC5D)\u2014can prevent BCMA escape\u2013mediated relapse in a model of multiple myeloma. To identify an optimal approach, we compare subtherapeutic doses of different forms of dual-targeted cellular therapy. These include; (i) parallel-produced and pooled mono-targeted CAR T cells, (ii) bicistronic constructs expressing distinct CARs from a single vector, and (iii) a dual-scFv \u201csingle-stalk\u201d CAR design. When targeting BCMA-negative disease, bicistronic and pooled approaches had the highest efficacy, whereas for dual-antigen\u2013expressing disease, the bicistronic approach was more efficacious than the pooled approach. Mechanistically, expressing two CARs on a single cell enhanced the strength of CAR T-cell\/target cell interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Myeloma frequently relapses post-CAR T-cell therapy; antigen escape\u2013mediated relapse can be mitigated with upfront dual-targeting (BCMA\/GPRC5D). A bicistronic vector encoding two CARs avoids the challenge of parallel manufacturing separate CAR T-cell products, while providing superior efficacy; this dual-targeted approach may enhance the durability of responses to cellular therapy for myeloma.<\/jats:p>\n                    <jats:p>See related commentary by Simon and Riddell, p. 130.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 127<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-20-0020","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T14:15:12Z","timestamp":1594044912000},"page":"146-154","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":219,"title":["Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape\u2013Driven Relapse in Multiple Myeloma"],"prefix":"10.1158","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"first","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-4373","authenticated-orcid":false,"given":"Mette","family":"Staehr","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Lopez","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-850X","authenticated-orcid":false,"given":"Khong Y.","family":"Ng","sequence":"additional","affiliation":[{"name":"2Sloan Kettering Institute, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9039-3474","authenticated-orcid":false,"given":"Yunxin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Godfrey","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"Purdon","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Ponomarev","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Guido","family":"Wendel","sequence":"additional","affiliation":[{"name":"2Sloan Kettering Institute, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"4Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-7587","authenticated-orcid":false,"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"5Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"2024012519360010400_bib1","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024012519360010400_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14694\/EdBook_AM.2014.34.199","article-title":"Where we were, where we are, where we are going: progress in multiple myeloma","volume":"34","author":"Bergsagel","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2024012519360010400_bib3","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2014-10-551531","article-title":"How I treat relapsed myeloma","volume":"125","author":"Blad\u00e9","year":"2015","journal-title":"Blood"},{"key":"2024012519360010400_bib4","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"2024012519360010400_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clml.2019.02.004","article-title":"Immunotherapy in multiple myeloma: accelerating on the path to the patient","volume":"19","author":"Ghobrial","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024012519360010400_bib6","first-page":"2487","article-title":"Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies","volume":"3","author":"Cohen","year":"2019","journal-title":"Blood"},{"key":"2024012519360010400_bib7","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"2024012519360010400_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol"},{"key":"2024012519360010400_bib9","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"2024012519360010400_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024012519360010400_bib11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2024012519360010400_bib12","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","article-title":"Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector","volume":"26","author":"Smith","year":"2018","journal-title":"Mol Ther"},{"key":"2024012519360010400_bib13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024012519360010400_bib14","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"2024012519360010400_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2024012519360010400_bib16","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024012519360010400_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2017","journal-title":"Nat Med"},{"key":"2024012519360010400_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2024012519360010400_bib19","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"2024012519360010400_bib20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"2024012519360010400_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"Antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2024012519360010400_bib22","doi-asserted-by":"crossref","first-page":"e0119546","DOI":"10.1371\/journal.pone.0119546","article-title":"NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease","volume":"10","author":"Lawson","year":"2015","journal-title":"PLoS One"},{"key":"2024012519360010400_bib23","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1016\/j.celrep.2018.08.034","article-title":"Single-cell acoustic force spectroscopy: resolving kinetics and strength of T cell adhesion to fibronectin","volume":"24","author":"Kamsma","year":"2018","journal-title":"Cell Rep"},{"key":"2024012519360010400_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nmeth.3183","article-title":"Acoustic force spectroscopy","volume":"12","author":"Sitters","year":"2014","journal-title":"Nat Methods"},{"key":"2024012519360010400_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"}],"updated-by":[{"DOI":"10.1158\/2643-3230.bcd-24-0017","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000}}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/2\/146\/3409313\/146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/2\/146\/3409313\/146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T14:36:48Z","timestamp":1706193408000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/1\/2\/146\/35114\/Defining-an-Optimal-Dual-Targeted-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,6]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-20-0020","relation":{},"ISSN":["2643-3249","2643-3230"],"issn-type":[{"value":"2643-3249","type":"electronic"},{"value":"2643-3230","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}